Hahn L, Helmrich N, Herebian D, Mayatepek E, Drebber U, Domann E, Olejniczak S, Weigel M, Hain T, Rath T, Wirtz S, Mollenkopf HJ, Schmidt N, Ewers C, Baier A, Churin Y, Windhorst A, Weiskirchen R, Steinhoff U, Roeb E, Roderfeld M (2020)
Publication Type: Journal article
Publication year: 2020
Book Volume: 9
Journal Issue: 9
DOI: 10.3390/cells9091949
The Th2 cytokine IL-13 is involved in biliary epithelial injury and liver fibrosis in patients as well as in animal models. The aim of this study was to investigate IL-13 as a therapeutic target during short term and chronic intrahepatic cholestasis in an Abcb4-knockout mouse model (Abcb4-/-). Lack of IL-13 protected Abcb4-/- mice transiently from cholestasis. This decrease in serum bile acids was accompanied by an enhanced excretion of bile acids and a normalization of fecal bile acid composition. In Abcb4-/-/IL-13-/- double knockout mice, bacterial translocation to the liver was significantly reduced and the intestinal microbiome resembled the commensal composition in wild type animals. In addition, 52-week-old Abcb4-/-IL-13-/- mice showed significantly reduced hepatic fibrosis. Abcb4-/- mice devoid of IL-13 transiently improved cholestasis and converted the composition of the gut microbiota towards healthy conditions. This highlights IL-13 as a potential therapeutic target in biliary diseases.
APA:
Hahn, L., Helmrich, N., Herebian, D., Mayatepek, E., Drebber, U., Domann, E.,... Roderfeld, M. (2020). IL-13 as Target to Reduce Cholestasis and Dysbiosis in Abcb4 Knockout Mice. Cells, 9(9). https://doi.org/10.3390/cells9091949
MLA:
Hahn, Luisa, et al. "IL-13 as Target to Reduce Cholestasis and Dysbiosis in Abcb4 Knockout Mice." Cells 9.9 (2020).
BibTeX: Download